🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I was interviewed for Sky News on behalf of the AMETHYST team about our trial comparing two psychological therapies for people who hear voices. You can check out the interview and demo of avatar therapy here (1/2) skynews.com.au/lifestyle/heal…

Unimelb Open Day: Medical Research Institutes. Orygen is a great place if you are considering pursuing a research career in psychiatry #orygen #phd #research

APPLY NOW | If you're a clinician, researcher, someone who's experienced (or is at risk of experiencing) psychosis, or your loved one has, the 2024 AEPCC Forum is for you. For more info and to apply to attend by 20 September: bit.ly/3yPkgil

NEWS | The Australian Early Psychosis Collaborative Consortium (AEPCC) has received a major grant to expand its Clinical Quality Registry at up to 20 more early psychosis clinical services nationally. Read on: bit.ly/3XcvuFK

Huge thanks to Wellcome Lynsey Bilsland @niallpboyce Prof Miranda Wolpert for the visionary support to get this venture launched. And to Australia’s NHMRC & MRFF for support to sustain & expand it

Many thanks to the Wellcome trust and MRFF and all our fantastic partners for making this happen - really important that mental health has the opportunity to see the major benefits of registries which has been the case in many other areas of healthcare

This will be the 15th IEPA conference since the first in Melbourne in 1996. Early intervention has gained huge momentum and currency in mental health but is still not routine or standard care. We need to redouble our research &translation efforts IEPA Orygen

A new FDA approved schizophrenia treatment by Bristol Myers Squibb (Bristol Myers Squibb) is the first new approach for treating the condition in over 50 years. Lynsey Bilsland, our Head of Mental Health Translation, tells us more about the breakthrough 👇 wellcome.org/news/new-treat…

.Wellcome is in the enviable position of supporting innovative mental health science 🧪and development of new interventions 💊📱. Next step - to deliver these at scale. This is where the Coalition of Mental Health Investment (CMHI) comes in. statnews.com/2024/10/07/men…

Around 1 in 300 people worldwide are affected by schizophrenia. Antipsychotic drugs are commonly used to treat the condition, but they don’t work for everyone. Last month, the FDA approved a new drug called Cobenfy from Bristol Myers Squibb– and the impact could be huge. [1/3]

The dataset, of 1245 individuals at ultra-high risk (UHR) of psychosis, has been used in a new Uni of Adelaide study to analyse the transition to psychosis and develop a model for predicting an individual’s risk of this transition. More: bit.ly/3U68YxD

Fantastic results from AvatarTherapy - read the paper see 👇

For those who remain hesitant.

My short book review for BJPsych Journals on 'Marijuana and Madness' (3rd edn). Edited by Deepak D'Souza, David Castle and Sir Robin Murray. Cambridge University Press. 2023. The British Journal of Psychiatry Royal College of Psychiatrists bit.ly/4fK7tNT

The ISPG mourns the loss of Dr. Tim Crow, a visionary researcher and founding member of our community. His contributions to psychiatric genetics, especially schizophrenia research, have been invaluable.

Some of the most pressing questions about psychosis and mental ill-health were addressed when the lived experience psychosis community, researchers and clinicians converged for the 2024 AEPCC Forum. Read on: bit.ly/3Z2mcNG

Our guideline for the use of metformin to prevent antipsychotic-induced weight gain has just been published in Schizophrenia Bulletin. Read the full paper here: academic.oup.com/schizophreniab… A 🧵of the key points

Congratulations to Orygen's four newest Associate Professors: Dominic Dwyer, Kate Filia, Zac Seidler and Caroline Gao! More: bit.ly/41s9iuU

New IDEA Risk-stratified Cohort (IDEA-RiSCo) paper: No prediction without prevention: A global qualitative study of attitudes toward using a prediction tool for risk of developing depression during adolescence - bit.ly/4fIPGX4 @gmhequity @prodiahcpa Institute of Psychiatry, Psychology & Neuroscience ESRC Centre for Society and Mental Health Valeria Mondelli @AnnaViduani

Orygen has launched a series of new CAARMS resources to help clinicians identify and support young people at risk of psychosis. They include an updated version of the assessment tool (CAARMS 23), a new rating sheet + a comprehensive training module: bit.ly/4kDuhSG